USFDA issues warning letter to Wockhardt's US arm
New Delhi : Drug firm Wockhardt said the US health regulator has issued a warning letter to its step down subsidiary Morton Grove Pharmaceuticals Inc.
"The United States Food and Drug Administration (USFDA) has issued a warning letter to Morton Grove Pharmaceuticals Inc, USA, a stepdown Subsidiary of the company," Wockhardt said in a filing to BSE.
The company, however, did not provide any details about the reasons for the issuance of warning letter and when it was issued.
"This would mean that current portfolio of the company will continue to be made available in the market. However, new approvals will be withheld till resolution," it added.
The company, with the help of the consultants, has already initiated appropriate measures since last several months to address the issues raised by USFDA," Wockhardt said.
Shares of Wockhardt closed at Rs 751.10 per scrip on BSE, down 0.05 per cent from previous close.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd